The Tablet

The Tablet is a series of short publications produced by KPMG’s Global Pharmaceutical practice that aims to address topical issues in the pharmaceuticals industry.

The impact of comparative effectiveness research on the pharmaceutical industry

Comparative effectiveness research (CER) can represent a strategic opportunity for companies to develop a patient-centric business model designed to increase their competitive advantage and position themselves for future growth. Read full report

Inside the current issue

Basic goals of CER

The basic goal of CER is to improve clinical decision-making and help patients get the most effective care they need.

Recent controversies

Despite a general consensus that CER can help improve clinical decision making, CER has become a subject of strong debate.

Issues for pharmaceutical companies

Several issues can be noted that may have a significant impact on pharmaceutical companies, such as limitations on innovation, increased costs and greater involvement of payers.

Conclusion

Pharmaceutical companies can use CER as a powerful tool in developing strategies to address their business goals.

Sign up now

Subscribe to selected content and receive email alerts when new content is available for viewing on this site.

Already a member? Login

Not a member? Register

Latest articles & publications

	Going Social

	Agenda – Insights into growth, performance and governance

	Clarity in the Cloud



	More articles and publications

Subscribe to related feeds

Pharmaceuticals

© 2012 KPMG International Cooperative (“KPMG International”), a Swiss entity. Member firms of the KPMG network of independent firms are affiliated with KPMG International. KPMG International provides no client services. No member firm has any authority to obligate or bind KPMG International or any other member firm vis-à-vis third parties, nor does KPMG International have any such authority to obligate or bind any member firm. All rights reserved.